Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast

Foghorn Therapeutics (NASDAQ:FHTX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Foghorn Therapeutics and Estrella Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-294.16%	N/A	-29.62%
Estrella Immunopharma	N/A	-1,132.38%	-411.91%

Earnings and Valuation

This table compares Foghorn Therapeutics and Estrella Immunopharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$22.60 million	10.93	-$86.62 million	($1.13)	-3.87
Estrella Immunopharma	N/A	N/A	N/A	($0.34)	-5.32

Estrella Immunopharma has lower revenue, but higher earnings than Foghorn Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Foghorn Therapeutics has a beta of 3.04, indicating that its stock price is 204% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Insider and Institutional Ownership

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Foghorn Therapeutics and Estrella Immunopharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1	0	5	2	3.00
Estrella Immunopharma	1	0	1	0	2.00

Foghorn Therapeutics currently has a consensus target price of $10.71, suggesting a potential upside of 145.18%. Estrella Immunopharma has a consensus target price of $16.00, suggesting a potential upside of 783.98%. Given Estrella Immunopharma’s higher probable upside, analysts clearly believe Estrella Immunopharma is more favorable than Foghorn Therapeutics.

Summary

Foghorn Therapeutics beats Estrella Immunopharma on 9 of the 13 factors compared between the two stocks.

About Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Estrella Immunopharma

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.